Tender Offer and Merger Details - Roche's subsidiary, Blue Giant Acquisition Corp, accepted approximately 64,991,586 shares of Poseida's common stock, representing 66.11% of the total outstanding shares, in the tender offer [1] - The tender offer price was $9.00 per share in cash, plus a non-tradeable contingent value right (CVR) for potential additional payments of up to $4.00 per share [8] - Roche plans to complete the acquisition of Poseida through a merger, converting all remaining shares into the same consideration as the tender offer, after which Poseida will become a wholly owned subsidiary of Roche and delist from Nasdaq [9] Company Overviews - Poseida Therapeutics is a clinical-stage biopharmaceutical company focused on allogeneic cell therapies and genetic medicines, with a pipeline targeting hematologic cancers, autoimmune diseases, and solid tumours [2] - Roche, founded in 1896, is the world's largest biotechnology company and a global leader in in-vitro diagnostics, with a focus on personalised healthcare and innovative medicines [3] Additional Information - Roche has a long-standing commitment to sustainability, aiming for net zero by 2045 through initiatives like the Science Based Targets and Sustainable Markets Initiative [10] - Genentech in the US is a wholly owned member of the Roche Group, and Roche holds a majority stake in Chugai Pharmaceutical, Japan [10]

Delhi, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights: Bispecific Antibodies Development Proprietary Platforms Insight: > 30 PlatformsGlobal Bispecific Antibodies Market Size Yearly and Quarterly Sales (2018 till 2024)Global Bispecific Antibodies Market Size 2024: > USD 8.5 BillionGlobal Bispecific Antibodies Market Forecast Till 2029Approved Bispecific Antibodies Yearly and Quarterly Sales (2018 till 2024)Ap ...

Company Performance - Roche (OTCQX: RHHBY) has been a middling performer since the last update, with concerns about the pipeline weighing on its performance despite healthy current financials [1] Analyst Disclosure - The analyst has a beneficial long position in Roche shares through stock ownership, options, or other derivatives [1] - The article expresses the analyst's own opinions and is not influenced by compensation or business relationships with the mentioned company [1] Seeking Alpha Disclosure - Seeking Alpha's disclosure emphasizes that past performance does not guarantee future results and does not provide investment recommendations or advice [2] - The views expressed in the article may not reflect those of Seeking Alpha as a whole, and the platform is not a licensed securities dealer, broker, or investment adviser [2]

Group 1 - Goldman Sachs has downgraded Roche Holding AG to a sell rating, maintaining a target price of 265 Swiss Francs [1] - The downgrade is related to Roche's Parkinson's disease candidate drug failing to meet key objectives in mid-stage studies, although results suggest potential clinical benefits in early Parkinson's disease treatment [1] - Other investment banks, including JPMorgan and Deutsche Bank, have also issued sell ratings on Roche Holding AG [2] Group 2 - Roche Holding AG is a research-based healthcare company with operations in pharmaceuticals and diagnostics [2] - Despite recent progress in certain areas, such as the approval of Vabysmo pre-filled syringes in Europe and positive long-term data in lymphoma treatment, setbacks in Parkinson's disease drug development and negative ratings from multiple investment banks have put pressure on its stock price [2]

PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpointsPrasinezumab continues to be well tolerated and no new safety signals were observed Roche is further evaluating the data and will work together with health authorities to determine next steps Basel, 19 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson’s disease, ...

Roche (RHHBY) announced that the European Medicines Agency has approved a prefilled syringe (PFS) of the ophthalmology drug Vabysmo (faricimab).The regulatory body approved Vabysmo PFS for use in the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).In the past three months, shares of Roche have lost 9.1% compared with the industry’s 14.3% decline.Image Source: Zacks Investment ResearchMore on RHHB ...

The new cobas 6800/8800 systems 2.0 enhances throughput, run flexibility, enables sample prioritisation and is available as an upgrade to existing systems in healthcare settings around the world.Laboratories can now perform a wider range of tests on a single solution, simplifying laboratory logistics and helping to optimise the use of resources. Basel, 13 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE certification of the new cobas® 6800/8800 systems 2.0. The update significantly ...

Roche (RHHBY) announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking expanded use of Columvi (glofitamab) for second-line relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) for review. The eligible population includes DLBCL patients who have received at least one prior line of treatment (second-line setting) and are not candidates for autologous stem cell transplant. A final decision from the regulatory body is expected on July 20, 2025.Please note ...

Application is based on data from the phase III STARGLO study where Columvi plus chemotherapy showed a statistically significant and clinically meaningful improvement in overall survival1,2 This regimen could provide an off-the-shelf, fixed-duration treatment option for patients to start soon after diagnosis, which is important for those who are at high-risk of disease progressionImproving survival outcomes is needed for people with an aggressive disease like relapsed or refractory DLBCL, especially those w ...

Core Points - Amanda Roche, Vice President and Finance Department Supervisor at Unity Bank, has been recognized as a 2024 New Leader in Banking by the New Jersey Bankers Association, highlighting her significant contributions to the New Jersey banking sector [1][2] - Roche is one of only 22 banking professionals under the age of 40 to receive this recognition, showcasing her leadership among peers in the industry [2] - The selection process for the award involved evaluation of leadership qualities such as confidence, decision-making capabilities, and community service commitment, assessed by five independent judges [3] Company Overview - Unity Bancorp, Inc. is the parent company of Unity Bank, which operates 21 branches across New Jersey and the Lehigh Valley, Pennsylvania, providing community-focused commercial banking services [6] - Unity Bank offers a range of services including deposit accounts, loans, and digital services, emphasizing its commitment to the local community [6] - The awards ceremony took place on November 7, 2024, at The Stone House at Stirling Ridge in Warren, New Jersey, celebrating the achievements of emerging banking professionals [5]